참고문헌 (60)

1. Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci U S A 2004;101:6146-51. 

   상세보기

2. Peak CM, Childs LM, Grad YH, Buckee CO. Comparing nonpharmaceutical interventions for containing emerging epidemics. Proc Natl Acad Sci U S A 2017;114:4023-8. 

   상세보기

3. Weber DJ, Rutala WA, Fischer WA, Kanamori H, Sickbert-Bennett EE. Emerging infectious diseases: focus on infection control issues for novel coronaviruses (severe acute respiratory syndrome-CoV and Middle East respiratory syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian influenza viruses, A(H5N1) and A(H7N9). Am J Infect Control 2016;44:e91-100. 

4. Park Y, Huh IS, Lee J, Kang CR, Cho SI, Ham HJ, et al. Application of testing-tracing-treatment strategy in response to the COVID-19 outbreak in Seoul, Korea. J Korean Med Sci 2020;35:e396. 

   상세보기

5. Haber MJ, Shay DK, Davis XM, Patel R, Jin X, Weintraub E, et al. Effectiveness of interventions to reduce contact rates during a simulated influenza pandemic. Emerg Infect Dis 2007;13:581-9. 

   상세보기

6. World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines [Internet]. Geneva: WHO; 2021 [cited 2021 Mar 12]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. 

7. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74. 

   상세보기

8. Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta Mol Basis Dis 2020;1866:165878. 

   상세보기

9. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281-292.e6. 

   상세보기

10. Sternberg A, Naujokat C. Structural features of coronavirus SARS-CoV-2 spike protein: targets for vaccination. Life Sci 2020;257:118056. 

    상세보기

11. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 2020;41:1141-9. 

    상세보기

12. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020;9:382-5. 

    상세보기

13. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med 2020;383:2439-50. 

    상세보기

14. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 - Preliminary report. N Engl J Med 2020;383:1920-31. 

    상세보기

15. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:467-78. 

    상세보기

16. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine. N Engl J Med 2021;NEJMoa2034201. 

17. World Health Organization. Status of COVID-19 vaccines within WHO EUL/PQ evaluation process [Internet]. Geneva: WHO; 2021 [cited 2021 Mar 16]. Available from: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_10March2021.pdf. 

18. Humphreys IR, Sebastian S. Novel viral vectors in infectious diseases. Immunology 2018;153:1-9. 

    상세보기

19. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol 2021;21:73-82. 

    상세보기

20. Krammer F. SARS-CoV-2 vaccines in development. Nature 2020;586:516-27. 

    상세보기

21. Pichichero ME. Understanding messenger RNA and other SARS-CoV-2 vaccines [Internet]. Parsippany: MD Edge; 2020 [cited 2021 Mar 28]. Available from: https://www.mdedge.com/hematology-oncology/article/233491/coronavirus-updates/understanding-messenger-rna-and-other-sars. 

22. Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 2020;586:567-71. 

    상세보기

23. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med 2020;383:1544-55. 

    상세보기

24. Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol Ther 2014;22:668-74. 

    상세보기

25. Zhang C, Zhou D. Adenoviral vector-based strategies against infectious disease and cancer. Hum Vaccin Immunother 2016;12:2064-74. 

    상세보기

26. Afrough S, Rhodes S, Evans T, White R, Benest J. Immunologic dose-response to adenovirus-vectored vaccines in animals and humans: a systematic review of dose-response studies of replication incompetent adenoviral vaccine vectors when given via an intramuscular or subcutaneous route. Vaccines (Basel) 2020;8:131. 

    상세보기

27. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603-15. 

    상세보기

28. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-16. 

    상세보기

29. Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111. 

    상세보기

30. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021;397:881-91. 

    상세보기

31. Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med, in press 2021. 

32. Vaccines and Related Biological Products Advisory Committee. COVID-19 vaccine Ad26.COV2.S sponsor briefing document [Internet]. Beerse: Janssen; 2021 [cited 2021 Feb 21]. Available from: https://www.fda.gov/media/146219/download. 

33. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med, in press 2021. 

34. Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med, in press 2021. 

35. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med, in press 2021. 

36. European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets [Internet]. Amsterdam: EMA; 2021 [cited 2021 Mar 20]. Available from: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood. 

37. European Medicines Agency. COVID-19 vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - Vaccine's benefits currently still outweigh risks - Update [Internet]. Amsterdam: EMA; 2021 [cited 2021 Apr 1]. Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-investigating-cases-thromboembolic-events-vaccines-benefits. 

38. Ostergaard SD, Schmidt M, Horvath-Puho E, Thomsen RW, Sorensen HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet 2021;397:1441-3. 

    상세보기

39. Mahase E. AstraZeneca vaccine: blood clots are "extremely rare" and benefits outweigh risks, regulators conclude. BMJ 2021;373:n931. 

    상세보기

40. Korea Disease Control and Prevention Agency. Resuming some pending AstraZeneca vaccinations from April 12th [Internet]. Cheongju: KDCA; 2021 [cited 2021 Apr 27]. Available from: http://www.kdca.go.kr/gallery.es?mida20503030300&bid0004&b_list9&actview&list_no145062&nPage1&vlist_no_npage1&keyField&keyWord&orderby. 

41. Centers for Disease Control and Prevention (US). CDC recommends use of Johnson & Johnson's Janssen COVID-19 vaccine resume [Internet]. Atlanta: CDC; 2021 [cited 2021 Apr 27]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html. 

42. Pfizer. Studying the COVID-19 vaccine for children [Internet]. New York: Pfizer; 2021 [cited 2021 Apr 5]. Available from: https://www.pfizer.com/science/clinical-trials/children. 

43. Pfizer. Pfizer-BioNTech announce positive topline results of pivotal COVID-19 vaccine study in adolescents [Internet]. New York: Pfizer; 2021 [cited 2021 Apr 17]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal. 

44. Moderna. A COVID-19 vaccine study for children (Kidcove Study Trial ID: NCT04796896) [Internet]. Cambridge: Moderna; 2021 [cited 2021 Mar 31]. Available from: https://connect.trialscope.com/studies/0e8fc8e6-5782-46fd-8b03-0994a5ad8b41. 

45. Moderna TX, Inc. A study to evaluate safety and effectiveness of mRNA-1273 vaccine in healthy children between 6 months of age and less than 12 years of age [Internet]. Bethesda: National Library of Medicine; 2021 [cited 2021 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04796896. 

46. National Institute for Health Research (UK). First children's COVID-19 vaccine trial open [Internet]. London: NIHR; 2021 [cited 2021 Mar 31]. Available from: https://www.nihr.ac.uk/news/first-childrens-covid-19-vaccine-trial-open/26870. 

47. Janssen. Johnson & Johnson expands phase 2a clinical trial of COVID-19 vaccine candidate to include adolescents [Internet]. Beerse: Janssen; 2021 [cited 2021 Apr 27]. Available from: https://www.jnj.com/johnson-johnson-expands-phase-2a-clinical-trial-of-covid-19-vaccine-candidate-to-include-adolescents. 

48. United Nations. World population prospects 2019: data query [Internet]. New York: UN; 2021 [cited 2021 Apr 14]. Available from: https://population.un.org/wpp/DataQuery/. 

49. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med 2020;382:1663-5. 

    상세보기

50. Han MS, Choi EH, Chang SH, Jin BL, Lee EJ, Kim BN, et al. Clinical characteristics and viral RNA detection in children with coronavirus disease 2019 in the Republic of Korea. JAMA Pediatr 2021;175:73-80. 

    상세보기

51. Jiehao C, Jin X, Daojiong L, Zhi Y, Lei X, Zhenghai Q, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis 2020;71:1547-51. 

    상세보기

52. Liu W, Zhang Q, Chen J, Xiang R, Song H, Shu S, et al. Detection of COVID-19 in children in early January 2020 in Wuhan, China. N Engl J Med 2020;382:1370-1. 

    상세보기

53. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis 2020;20:689-96. 

    상세보기

54. Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. Clin Exp Pediatr 2020;63:125-32. 

    원문보기 상세보기

55. American Academy of Pediatrics. Children and COVID-19: state-level data report [Internet]. Itasca: AAP; 2021 [cited 2021 Apr 2]. Available from: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/. 

56. Centers for Disease Control and Prevention (US). 2019-20 season's pediatric flu deaths tie high mark set during 2017-18 season [Internet]. Atlanta: CDC; 2021 [cited 2021 Mar 4]. Available from: https://www.cdc.gov/flu/spotlights/2019-2020/2019-20-pediatric-flu-deaths.htm#:~:textLinkedIn-,2019%2D20%20Season's%20Pediatric%20Flu%20Deaths%20Tie%20High,Set%20During%202017%2D18%20Season&textAugust%2021%2C%202020%20%E2%80%93%20CDC%20today,for%20last%20season%20to%20188. 

57. Goodman B. Children likely the 'leading edge' in spread of COVID-19 variants [Internet]. New York: Medscape; 2021 [cited 2021 Apr 17]. Available from: https://www.medscape.com/viewarticle/948584. 

58. Klass P, Ratner AJ. Vaccinating children against COVID-19 - The lessons of measles. N Engl J Med 2021;384:589-91. 

    상세보기

59. Anderson EJ, Campbell JD, Creech CB, Frenck R, Kamidani S, Munoz FM, et al. Warp speed for COVID-19 vaccines: Why are children stuck in neutral? Clin Infect Dis 2020;ciaa1425. 

60. Wong BLH, Ramsay ME, Ladhani SN. Should children be vaccinated against COVID-19 now? Arch Dis Child 2021;archdischild-2020-321225. 

저자의 다른 논문 :

최은화 (59)